SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
Titel:
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
Auteur:
Hecht, J. Randolph Cohn, Allen Dakhil, Shaker Saleh, Mansoor Piperdi, Bilal Cline-Burkhardt, Mika Tian, Ying Go, William Y.